Evaluation of an intracellular pharmacokinetic in vitro infection model as a tool to assess tuberculosis therapy

International Journal of Antimicrobial Agents

Volumn 29, Issue 2, 2007, Pages 212-216

  Cappelletty, Diane M ^a  

^a UNIVERSITY OF TOLEDO   (United States)

Author keywords

Intracellular; Isoniazid; Levofloxacin; Mycobacterium tuberculosis; Pharmacokinetic model; Rifampicin

Indexed keywords

ANTIMYCOBACTERIAL AGENT; ISONIAZID; LEVOFLOXACIN; RIFAMPICIN;

ARTICLE; BACTERIAL INFECTION; CELL CULTURE; CONTROLLED STUDY; DIFFUSION; DRUG HALF LIFE; HUMAN; HUMAN CELL; IN VITRO STUDY; INOCULATION; INTRACELLULAR KILLING; MACROPHAGE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; CELL LINE; HALF-LIFE; HUMANS; ISONIAZID; MYCOBACTERIUM TUBERCULOSIS; OFLOXACIN; RIFAMPIN;

EID: 33846049242     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2006.10.001     Document Type: Article

References (13)

1. Skinner P.S., Furney S.K., Kleinert D.A., and Orme I.M. Comparison of activities of fluoroquinolones in murine macrophages infected with Mycobacterium tuberculosis. Antimicrob Agents Chemother 39 (1995) 750-753
2. Carlone N.A., Acocella G., Cuffini A.M., and Forno-Pizzoglio M. Killing of macrophage-ingested mycobacteria by rifampicin, pyrazinamide, and pyrazinoic acid alone and in combination. Am Rev Respir Dis 132 (1985) 1274-1277
3. Crowle A.J., Sbarbaro J.A., Judson F.N., Douvas G.S., and May M.H. Inhibition by streptomycin of tubercle bacilli within cultured human macrophages. Am Rev Respir Dis 130 (1984) 839-844
4. Crowle A.J., Sbarbaro J.A., Judson F.N., and May M.H. The effect of ethambutol on tubercle bacilli within cultured human macrophages. Am Rev Respir Dis 132 (1985) 742-745
5. Sbarbaro J.A., Iseman M.D., and Crowle A.J. The combined effect of rifampin and pyrazinamide within the human macrophage. Am Rev Respir Dis 146 (1992) 1448-1451
6. Mor N., Vanderkolk J., and Heifets L. Inhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophages. Antimicrob Agents Chemother 38 (1994) 1161-1164
7. Mor N., Simon B., Mezo N., and Heifets L. Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages. Antimicrob Agents Chemother 39 (1995) 2073-2077
8. Hultén K., Rigo R., Gustafsson I., and Engstrand L. New pharmacokinetic in vitro model for studies of antibiotic activity against intracellular microorganisms. Antimicrob Agents Chemother 40 (1996) 2727-2731
9. Agrawal S., Kaur K., Singh I., Bhade S.R., Kaul C.L., and Panchagnula R. Assessment of bioequivalence of rifampicin, isoniazid and pyrazinamide in a four drug fixed dose combination with separate formulations at the same dose levels. Int J Pharm 233 (2002) 169-177
10. Blaser J. In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives. J Antimicrob Chemother 15 Suppl. A (1985) 125-130
11. Wright D.H., Gunderson B.W., Hovde L.B., Ross G.H., Ibrahim K.H., and Rotschafer J.C. Comparative pharmacodynamics of three newer fluoroquinolones versus six strains of staphylococci in an in vitro model under aerobic and anaerobic conditions. Antimicrob Agents Chemother 46 (2002) 1561-1563
12. White R.L., Friedrich L.V., Manduru M., Mihm L.B., and Bosso J.A. Comparative in vitro pharmacodynamics of imipenem and meropenem against ATCC strains of Escherichia coli, Staphylococcus aureus and Bacteroides fragilis. Diagn Microbiol Infect Dis 39 (2001) 39-47
13. Cappelletty D.M. Evaluation of several dosing regimens of cefepime, with various simulations of renal function, against clinical isolates of Pseudomonas aeruginosa in a pharmacodynamic infection model. Antimicrob Agents Chemother 43 (1999) 129-133